Related Articles
PI3K inhibition sensitizes EGFR wild‑type NSCLC cell lines to erlotinib chemotherapy
The novel dual PI3K/mTOR inhibitor GDC-0941 synergizes with the MEK inhibitor U0126 in non-small cell lung cancer cells
A novel dual PI3Kα/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells
Synergistic interaction between MEK inhibitor and gefitinib in EGFR‑TKI‑resistant human lung cancer cells
RAD001 offers a therapeutic intervention through inhibition of mTOR as a potential strategy for esophageal cancer